Nyxoah Presents Promising DREAM Study Data at ISSS 2024

Nyxoah SA revealed significant results from its DREAM study at the ISSS 2024 Educational Update in Miami. The study demonstrated a 71.0% median reduction in Apnea-Hypopnea index (AHI) in patients with Obstructive Sleep Apnea (OSA) 12 months post-treatment.

82.0% of patients showed an AHI below 15, and 67.4% had an AHI below 10. Genio bilateral stimulation indicated a 71.0% reduction in supine AHI and 70.8% across all positions. Secondary endpoints signaled improvements in quality of life and sleepiness.

Chief Investigator Dr. B. Tucker Woodson confirmed the efficacy of Genio, with significant primary and secondary endpoint improvements. CEO Olivier Taelman emphasized the clinical validation of AHI reductions across sleep positions.

Safety results were consistent with other neuromodulation therapies. The DREAM study marks progress towards FDA approval, aiming to make Genio available to OSA patients in the US.